long intergenic non-protein coding RNA 2519Genealiases: []
Q-omics provides the consensus-scored LINC02519 profile across patient tissues and cancer cell-line models. LINC02519 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LINC02519 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, LINC02519 RNA expression shows 16,690 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight OV, COAD, and LUAD as cancer lineages where LINC02519 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02519 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02519 survival associations across molecular data types. LINC02519 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02519 RNA expression–survival associations across cancer types. High LINC02519 expression shows unfavorable associations in OV, KIRP, THCA, DLBC and UCEC, but favorable associations in BRCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for LINC02519 RNA expression.
This table summarizes LINC02519 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02519. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02519 shows lower tumor expression in LUSC, KICH and UCEC and higher tumor expression in COAD, BLCA and STAD. The COAD box plot shows higher LINC02519 RNA expression in tumor versus normal tissue (log2 FC = +0.186, t-test p < 0.001).
This table shows molecular features associated with LINC02519 in patient tissues and cancer cell lines. In patient samples, LINC02519 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
